Company: NCEL
Filing Date: 2025-03-31
Form Type: 425
Source: 0001213900-25-025889
Chunk: 93

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 425
Chunk 93
---
 __________________________________________

Title of Authorized Signatory: _________________________________________

Email Address of Authorized Signatory: _____________________________

Facsimile Number of Authorized Signatory: ____________________________________________

State of Incorporation of Purchaser: ___________________________________________

Address for Notice to Purchaser:

Address for Delivery of Securities to Purchaser (if not same as address
for notice):

Initial Closing Subscription Amount:

Initial Closing Preferred Shares: 242,424

Initial Closing Warrant: 157,576

Subsequent Closing Subscription Amount:

Subsequent Closing Preferred Shares: 121,212

Subsequent Closing Warrants: 78,788

EIN Number, if applicable, will be provided under separate cover

<div align='center'>51

[PURCHASER SIGNATURE PAGE TO NLS PHARMACEUTICS LTD.

SECURITIES PURCHASE AGREEMENT]</div>

IN WITNESS WHEREOF, the undersigned have caused
this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

Name of Purchaser: __________________________________

Signature of Authorized Signatory of Purchaser: _________________________________________

Name of Authorized Signatory: __________________________________________

Title of Authorized Signatory: _________________________________________

Email Address of Authorized Signatory: _____________________________

Facsimile Number of Authorized Signatory: ____________________________________________

State of Incorporation of Purchaser: ___________________________________________

Address for Notice to Purchaser:

Address for Delivery of Securities to Purchaser (if not same as address
for notice):

Initial Closing Subscription Amount:

Initial Closing Preferred Shares: 212,121

Initial Closing Warrant: 137,879

Subsequent Closing Subscription Amount:

Subsequent Closing Preferred Shares: 106,061

Subsequent Closing Warrants: 68,939

EIN Number, if applicable, will be provided under separate cover

<div align='center'>52

EXHIBIT A

ACCREDITED INVESTOR QUESTIONNAIRE

IN CONNECTION WITH INVESTMENT IN SECURITIES

NLS PHARMACEUTICS LTD.

PURSUANT TO SECURITIES PURCHASE AGREEMENT DATED MARCH 26, 2025</div>

TO : NLS Pharmaceutics Ltd.

PLEASE ANSWER ALL QUESTIONS.
If the appropriate answer is “None” or “Not Applicable”, so state. Please print or type your answers to all questions.
Attach additional sheets if necessary to complete your answers to any item.

Your answers will be kept strictly
confidential at all times. However, NLS Pharmaceutics